Compare Glenmark Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs LUPIN - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA LUPIN GLENMARK PHARMA/
LUPIN
 
P/E (TTM) x 11.5 -74.0 - View Chart
P/BV x 1.5 2.2 66.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 GLENMARK PHARMA   LUPIN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
LUPIN
Mar-19
GLENMARK PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs712986 72.2%   
Low Rs484720 67.1%   
Sales per share (Unadj.) Rs349.6369.5 94.6%  
Earnings per share (Unadj.) Rs32.813.4 244.6%  
Cash flow per share (Unadj.) Rs44.337.4 118.6%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.6303.7 65.4%  
Shares outstanding (eoy) m282.17452.49 62.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.72.3 74.0%   
Avg P/E ratio x18.263.6 28.6%  
P/CF ratio (eoy) x13.522.8 59.1%  
Price / Book Value ratio x3.02.8 107.1%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,625386,064 43.7%   
No. of employees `00012.017.7 68.1%   
Total wages/salary Rs m20,56131,513 65.2%   
Avg. sales/employee Rs Th8,196.09,453.8 86.7%   
Avg. wages/employee Rs Th1,708.11,782.0 95.9%   
Avg. net profit/employee Rs Th768.5343.0 224.0%   
INCOME DATA
Net Sales Rs m98,655167,182 59.0%  
Other income Rs m2,0813,640 57.2%   
Total revenues Rs m100,736170,822 59.0%   
Gross profit Rs m15,85828,822 55.0%  
Depreciation Rs m3,25910,850 30.0%   
Interest Rs m3,3463,078 108.7%   
Profit before tax Rs m11,33518,534 61.2%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m1,672-3,400 -49.2%   
Tax Rs m3,7569,017 41.7%   
Profit after tax Rs m9,2506,066 152.5%  
Gross profit margin %16.117.2 93.2%  
Effective tax rate %33.148.7 68.1%   
Net profit margin %9.43.6 258.4%  
BALANCE SHEET DATA
Current assets Rs m66,968138,536 48.3%   
Current liabilities Rs m40,21161,299 65.6%   
Net working cap to sales %27.146.2 58.7%  
Current ratio x1.72.3 73.7%  
Inventory Days Days8384 99.5%  
Debtors Days Days81112 72.2%  
Net fixed assets Rs m33,322127,516 26.1%   
Share capital Rs m282905 31.2%   
"Free" reserves Rs m55,770136,517 40.9%   
Net worth Rs m56,052137,422 40.8%   
Long term debt Rs m35,73866,417 53.8%   
Total assets Rs m132,888279,494 47.5%  
Interest coverage x4.47.0 62.5%   
Debt to equity ratio x0.60.5 131.9%  
Sales to assets ratio x0.70.6 124.1%   
Return on assets %9.53.3 289.7%  
Return on equity %16.54.4 373.9%  
Return on capital %17.88.9 200.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99859,414 106.0%   
Fx outflow Rs m22,85922,282 102.6%   
Net fx Rs m40,14037,132 108.1%   
CASH FLOW
From Operations Rs m13,24216,660 79.5%  
From Investments Rs m-6,990-32,825 21.3%  
From Financial Activity Rs m-7,3877,441 -99.3%  
Net Cashflow Rs m-2,971-8,724 34.1%  

Share Holding

Indian Promoters % 48.3 46.6 103.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 6.9 11.3 61.1%  
FIIs % 34.4 31.9 107.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.1 104.0%  
Shareholders   56,727 98,259 57.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   WYETH LTD  IPCA LABS  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Lower; Energy and Healthcare Stocks Witness Selling(Closing)

Indian share markets witnessed volatile trading activity throughout the day and ended marginally lower.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 25, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS